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Aim
There can now be little doubt that certain drug-resis-
t a n c em u t a t i o n sa r em o r el i k e l yt oe m e r g ei nv i r u s e so f
certain subtypes than others. Two of the best and most
practical examples of this are the emergence of the
V106M NNRTI mutation and the K65R NRTI mutation
in viruses of subtype C.
Methods
It is relevant that the use of newer more sensitive meth-
ods have been key in establishing the role that certain
drug-resistance mutations may play in both transmitted
and acquired drug resistance. In particular, the use of
allele-specific PCR assays (AS-PCR) and pyrosequencing
have been very useful in providing new insights.
Results
Among the reasons that more ultrasensitive assays may
sometimes be needed for more accurate assessments of
drug resistance is the differential effect of certain muta-
tions on viral replicative capacity. As an example, the
K65R mutation is known to adversely affect HIV repli-
cation, and this may be one of the reasons that it is
found relatively infrequently among individuals who fail
antiretroviral therapy. In contrast, the use of AS-PCR
for K65R in subtype C viruses has shown that this
method was able to detect the presence of this mutation
in an additional 4 of 30 samples who had tested negative
by bulk sequencing methods. Now, it also appears as
though the transmission of the K65R mutation, while
rare, can also be detected in higher numbers by AS-PCR
than bulk sequencing, and that this is also more com-
mon among subtype C than subtype B viruses. The
likely reason is that subtype C viruses are more prone
to develop K65R as a consequence of treatment failure
and are therefore more likely than subtype B viruses to
contain this mutation at the time that transmission
takes place. In the case of the M184V mutation, it has
also been observed that AS-PCR methods can detect
this substitution more efficiently than bulk sequencing
among newly-infected individuals.
Discussion
Thus, the reason that some resistance-associated muta-
tions are not commonly observed in newly-infected sub-
jects is not because they impact on the ability of HIV to
be transmitted but rather because they may quickly
revert to wild-type in the absence of drug pressure and
then be rapidly overgrown by wild-type variants.
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